March 25, 2013

Notification of the approval of a production and sales permit for NEOXY® Tape 73.5 mg, overactive bladder treatment medication (oxybutynin hydrochloride, transdermal therapeutic formulation, development code: HOB-294)

Hisamitsu Pharmaceutical Co., Ltd., (Head Office: Tosu city, Saga Prefecture, Japan; President & CEO: Hirotaka Nakatomi; hereinafter referred to as Hisamitsu) and Asahi Kasei Pharma Corp. (Head Office: Chiyoda-ku, Tokyo, Japan; President: Toshio Asano; hereinafter referred to as Asahi Kasei) are announcing that Hisamitsu has acquired an approval of manufacturing and sales permit for NEOXY® Tape 73.5 mg, an overactive bladder treatment medication (oxybutynin hydrochloride, transdermal therapeutic formulation, development code: HOB-294) as of today for which Hisamitsu had submitted an application in May 2012 in Japan.

This is a transdermal therapeutic formulation for oxybutynin hydrochloride developed as a tape-form drug using Hisamitsu's TDDS (transdermal drug delivery system) technology. The development was conducted in Japan with the expectation to sustain pharmacological effects by maintaining stable drug concentrations in the blood.

Hisamitsu and Asahi Kasei, which entered into a contract for joint sales in Japan as of December 10, 2012, will sell this product jointly.

Hisamitsu and Asahi Kasei are committed to further improving the quality of life of patients who suffer from overactive bladders by providing information on proper uses of this product.

Reference:

Trade name	NEOXY® Tape 73.5 mg
Active pharmaceutical ingredient	Oxybutynin hydrochloride
Indication	Urinary urgency, frequent urination, and urge urinary incontinence caused by overactive bladders
Dose and Administration	Usually apply one sheet (73.5 mg of oxybutynin hydrochloride) once a day on the lower abdomen, lower back, or thigh of an adult and replace every 24 hours.